Immunocore Financial Statements
NASDAQ: IMCRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunocore revenue and earnings
In fiscal 2025, Immunocore generated $400.0 million in revenue, up 29.0% from fiscal 2024, its 4th consecutive year of revenue growth. Immunocore reported a net loss of $35.5 million, compared with a loss of $51.1 million a year earlier. Gross margin was 98.7% (down from 99.1%) and operating margin -11.3%.
Diluted earnings per share came in at -$0.71. Over the last 4 fiscal years, IMCR's revenue has grown at a 82.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Immunocore income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|---|
| Revenue | 400.02M | 310.20M | 249.43M | 174.36M | 36.48M |
| Revenue growth (YoY) | +28.95% | +24.37% | +43.05% | +377.91% | — |
| Cost of Revenue | 5.09M | 2.73M | 1.04M | 1.09M | 0 |
| Gross Profit | 394.93M | 307.47M | 248.39M | 173.27M | 36.48M |
| Operating Expenses | 440.28M | 377.93M | 308.04M | 224.98M | 211.07M |
| Research & Development | 274.87M | 222.15M | 163.54M | 101.92M | 100.25M |
| Selling, General & Admin | 165.41M | 155.78M | 144.50M | 123.06M | 110.82M |
| Operating Income | -45.35M | -70.46M | -59.65M | -51.71M | -174.59M |
| Interest Expense | 12.17M | 18.84M | 5.15M | 5.41M | 5.57M |
| Other Income (Expense) | 19.73M | 14.20M | -897.00K | -1.68M | -73.00K |
| Pretax Income | -19.10M | -52.94M | -60.89M | -40.88M | -179.88M |
| Income Tax | 16.41M | -1.85M | -5.60M | 11.66M | 150.00K |
| Net Income | -35.51M | -51.09M | -55.29M | -52.54M | -180.03M |
| Net Income growth (YoY) | — | — | — | — | — |
| EPS (Basic) | -0.71 | -1.02 | -1.13 | -1.15 | -4.24 |
| EPS (Diluted) | -0.71 | -1.02 | -1.13 | -1.15 | -4.24 |
| Shares Outstanding (Basic) | 50.35M | 49.99M | 48.89M | 45.71M | 42.49M |
| Shares Outstanding (Diluted) | 50.35M | 49.99M | 48.89M | 45.71M | 42.49M |
| EBITDA | -42.25M | -66.26M | -55.55M | -46.41M | -166.99M |
| Gross Margin | 98.73% | 99.12% | 99.58% | 99.38% | 100.00% |
| Operating Margin | -11.34% | -22.71% | -23.91% | -29.66% | -478.53% |
| Net Margin | -8.88% | -16.47% | -22.17% | -30.13% | -493.45% |
This table shows 5 annual periods of Immunocore's income statement, from FY 2025 back to FY 2021, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow IMCR's reporting calendar. What is a income statement?